Enanta Pharmaceuticals (ENTA) EBITDA (2012 - 2026)

Enanta Pharmaceuticals has reported EBITDA for 15 years, with the latest figure at -$11.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 51.68% year-over-year to -$11.9 million; the trailing twelve-month figure through Mar 2026 stood at -$60.4 million (up 40.86% YoY), and the FY2025 full-year result was -$85.3 million, up 29.86% from the prior year.
• EBITDA for Q1 2026 stood at -$11.9 million, down from -$11.3 million in the prior quarter.
• The five-year high for EBITDA was -$11.3 million in Q4 2025, with the low at -$39.5 million in Q1 2023.
• Historically, EBITDA has averaged -$27.1 million across 5 years, with a median of -$29.9 million in 2024.
• Annual changes were most pronounced in 2023 — EBITDA fell 16.56% — and 2025, when it surged 52.2%.
• Enanta Pharmaceuticals' EBITDA stood at -$30.0 million in 2022, then retreated by 16.24% to -$34.9 million in 2023, then soared by 32.51% to -$23.5 million in 2024, then surged by 52.2% to -$11.3 million in 2025, then retreated by 5.32% to -$11.9 million in 2026.
• The last three EBITDA figures came in at -$11.9 million (Q1 2026), -$11.3 million (Q4 2025), and -$18.4 million (Q3 2025), per Business Quant data.